Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2024
0mins
Source: Benzinga
- 临床试验结果显示：哮喘治疗中的快速进展：临床试验结果显示，哮喘治疗中的快速进展，为广泛性焦虑障碍（GAD）患者带来潜在益处。
- 教育机构推动：开源学习框架提升心理治疗标准：Beckley Academy发布首个开源学习框架，旨在推动心理治疗标准，填补行业培训标准和认证的缺失。
- 生物科技公司签署协议：开发新型神经可塑性药物：Enveric Biosciences与另一生物技术公司签署三项非约束性协议，以外部许可方式开发治疗抑郁症、焦虑症和成瘾障碍的新型小分子药物。
- **心理治疗领域取得突破：抑
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GHRS
Wall Street analysts forecast GHRS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.420
Low
19.00
Averages
28.60
High
35.00
Current: 26.420
Low
19.00
Averages
28.60
High
35.00
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rapid Growth in Major Depressive Disorder Treatment Market
- Market Growth Potential: The global Major Depressive Disorder treatment market is projected to grow from approximately $20 billion in 2026 to nearly $36 billion by 2033, reflecting strong long-term demand and attracting billions in investment.
- Clinical Trial Progress: Helus Pharma's HLP003 has surpassed 88% enrollment in the Phase 3 APPROACH study for MDD, with topline data expected in Q4 2026, marking a significant step towards commercialization.
- Significant Efficacy: Phase 2 data for HLP003 demonstrated a ~23-point reduction in MADRS score at 12 months after two 16mg doses, achieving a 100% response rate and 71% remission rate, indicating its potential in treating treatment-resistant depression.
- Strategic Partnerships: Helus Pharma has partnered with TARA Mind to enhance access to mental health treatment for veterans and collaborates with leading mental health organizations to support HLP003 Phase 3 recruitment, further expanding its market impact.
See More
Helus Pharma's HLP003 Phase 3 Trial Enrollment Surpasses 86%
- Enrollment Milestone: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026, indicating the company's potential in the mental health treatment space.
- Clinical Trial Significance: Eric So noted that the continued enrollment progress underscores the execution of the clinical program, bringing them closer to the anticipated topline data release, which could provide a transformative treatment option for patients with major depressive disorder, enhancing the company's position in a competitive market.
- FDA Breakthrough Designation: HLP003 has received FDA Breakthrough Therapy Designation, aimed at expediting development and review, signaling significant improvement potential in treating major depressive disorder, thus boosting investor confidence in the program.
- Strong Market Demand: Major depressive disorder affects hundreds of millions globally, with traditional treatments offering limited relief; if HLP003 can validate its efficacy in Phase 3 trials, it could reshape the management of depression.
See More
Helus Pharma's HLP003 Phase 3 Trial Surpasses 86% Enrollment
- Significant Trial Progress: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough Therapy program on track for a topline data readout in Q4 2026, potentially offering a new treatment option for depression.
- Clinical Data Highlights: HLP003 demonstrated substantial efficacy in Phase 2 trials, with a ~23-point reduction in MADRS scores at 12 months, and an 18-week response rate of 75%, improving to 100% at 12 months, laying a solid foundation for the upcoming Phase 3 trial.
- Strong Market Demand: With millions affected by major depressive disorder and existing treatments often inadequate, HLP003's fast-acting, neuroplasticity-oriented approach could reshape depression management, addressing the urgent need for novel therapies in the market.
- Far-reaching Strategic Implications: The Breakthrough Therapy designation accelerates HLP003's development, positioning Helus Pharma to carve out a niche in a competitive landscape, and successful Phase 3 data could pave the way for future commercialization efforts.
See More
GH Research Announces Phase 2a Results for GH001 in Treating Post-Partum Depression
- Clinical Trial Results: GH Research PLC's Phase 2a trial results for GH001 indicate a significant average reduction of 35.4 points in depression scores among 10 postpartum depression patients over 8 days, demonstrating the drug's efficacy in alleviating postpartum depression symptoms.
- Rapid Relief Effect: Remarkably, 100% of patients achieved remission (MADRS below 10) within two hours of dosing, showcasing GH001's rapid action mechanism and potentially offering a new solution for postpartum depression treatment.
- Improvement in Maternal Functioning: The study also noted an average increase of 34.1 points in maternal functioning assessments, indicating GH001's positive impact on overall maternal well-being, further supporting its clinical application potential.
- Future Research Plans: GH Research stated that these results support further investigation of inhaled mebufotenin in larger randomized controlled trials, highlighting the company's strategic focus on addressing treatment-resistant depression.
See More
GH Research Reports Strong Cash Position Amid Q1 Loss
- Financial Performance: GH Research reported a Q1 GAAP EPS of -$0.31, indicating a loss; however, the company maintains a strong cash flow, reflecting ongoing investment in R&D.
- Cash Reserves: As of March 31, 2026, GH Research holds $267.3 million in cash, cash equivalents, and marketable securities, ensuring financial flexibility for future project advancements.
- Capital Raising: The company secured an additional $111.2 million in net cash proceeds from an underwritten offering in April 2026, which will support the advancement of GH001 into Phase 3 clinical trials, enhancing its market competitiveness.
- Market Outlook: With Trump signing legislation to expedite PTSD research, GH Research's prospects in psychedelic treatments, particularly for depression, appear promising, potentially opening new avenues for growth.
See More
GH Research Prices $117.5 Million Stock Offering
- Stock Offering Pricing: GH Research has priced an underwritten offering of 6.53 million ordinary shares at $18 each, aiming for gross proceeds of approximately $117.5 million, which will significantly bolster the company's financial resources for future initiatives.
- Underwriter Participation: The transaction was initiated by Lynx1 Capital Management, with participation from Deep Track Capital and Foresite Capital, while Stifel, Cantor Fitzgerald, and RBC Capital Markets serve as joint book-running managers, reflecting strong market confidence in the company.
- Closing Schedule: The offering is expected to close on April 30, indicating the company's active engagement in capital markets and urgent funding needs, which may influence the advancement of its upcoming projects.
- Market Reaction: Despite a 1% decline in GH Research's shares during premarket trading, the offering is still viewed as a positive step towards enhancing the company's financial position, potentially boosting investor confidence in the long run.
See More
Rapid Growth in Major Depressive Disorder Treatment Market
- Market Growth Potential: The global Major Depressive Disorder treatment market is projected to grow from approximately $20 billion in 2026 to nearly $36 billion by 2033, reflecting strong long-term demand and attracting billions in investment.
- Clinical Trial Progress: Helus Pharma's HLP003 has surpassed 88% enrollment in the Phase 3 APPROACH study for MDD, with topline data expected in Q4 2026, marking a significant step towards commercialization.
- Significant Efficacy: Phase 2 data for HLP003 demonstrated a ~23-point reduction in MADRS score at 12 months after two 16mg doses, achieving a 100% response rate and 71% remission rate, indicating its potential in treating treatment-resistant depression.
- Strategic Partnerships: Helus Pharma has partnered with TARA Mind to enhance access to mental health treatment for veterans and collaborates with leading mental health organizations to support HLP003 Phase 3 recruitment, further expanding its market impact.
See More
Helus Pharma's HLP003 Phase 3 Trial Enrollment Surpasses 86%
- Enrollment Milestone: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026, indicating the company's potential in the mental health treatment space.
- Clinical Trial Significance: Eric So noted that the continued enrollment progress underscores the execution of the clinical program, bringing them closer to the anticipated topline data release, which could provide a transformative treatment option for patients with major depressive disorder, enhancing the company's position in a competitive market.
- FDA Breakthrough Designation: HLP003 has received FDA Breakthrough Therapy Designation, aimed at expediting development and review, signaling significant improvement potential in treating major depressive disorder, thus boosting investor confidence in the program.
- Strong Market Demand: Major depressive disorder affects hundreds of millions globally, with traditional treatments offering limited relief; if HLP003 can validate its efficacy in Phase 3 trials, it could reshape the management of depression.
See More
Helus Pharma's HLP003 Phase 3 Trial Surpasses 86% Enrollment
- Significant Trial Progress: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough Therapy program on track for a topline data readout in Q4 2026, potentially offering a new treatment option for depression.
- Clinical Data Highlights: HLP003 demonstrated substantial efficacy in Phase 2 trials, with a ~23-point reduction in MADRS scores at 12 months, and an 18-week response rate of 75%, improving to 100% at 12 months, laying a solid foundation for the upcoming Phase 3 trial.
- Strong Market Demand: With millions affected by major depressive disorder and existing treatments often inadequate, HLP003's fast-acting, neuroplasticity-oriented approach could reshape depression management, addressing the urgent need for novel therapies in the market.
- Far-reaching Strategic Implications: The Breakthrough Therapy designation accelerates HLP003's development, positioning Helus Pharma to carve out a niche in a competitive landscape, and successful Phase 3 data could pave the way for future commercialization efforts.
See More
GH Research Announces Phase 2a Results for GH001 in Treating Post-Partum Depression
- Clinical Trial Results: GH Research PLC's Phase 2a trial results for GH001 indicate a significant average reduction of 35.4 points in depression scores among 10 postpartum depression patients over 8 days, demonstrating the drug's efficacy in alleviating postpartum depression symptoms.
- Rapid Relief Effect: Remarkably, 100% of patients achieved remission (MADRS below 10) within two hours of dosing, showcasing GH001's rapid action mechanism and potentially offering a new solution for postpartum depression treatment.
- Improvement in Maternal Functioning: The study also noted an average increase of 34.1 points in maternal functioning assessments, indicating GH001's positive impact on overall maternal well-being, further supporting its clinical application potential.
- Future Research Plans: GH Research stated that these results support further investigation of inhaled mebufotenin in larger randomized controlled trials, highlighting the company's strategic focus on addressing treatment-resistant depression.
See More
GH Research Reports Strong Cash Position Amid Q1 Loss
- Financial Performance: GH Research reported a Q1 GAAP EPS of -$0.31, indicating a loss; however, the company maintains a strong cash flow, reflecting ongoing investment in R&D.
- Cash Reserves: As of March 31, 2026, GH Research holds $267.3 million in cash, cash equivalents, and marketable securities, ensuring financial flexibility for future project advancements.
- Capital Raising: The company secured an additional $111.2 million in net cash proceeds from an underwritten offering in April 2026, which will support the advancement of GH001 into Phase 3 clinical trials, enhancing its market competitiveness.
- Market Outlook: With Trump signing legislation to expedite PTSD research, GH Research's prospects in psychedelic treatments, particularly for depression, appear promising, potentially opening new avenues for growth.
See More
GH Research Prices $117.5 Million Stock Offering
- Stock Offering Pricing: GH Research has priced an underwritten offering of 6.53 million ordinary shares at $18 each, aiming for gross proceeds of approximately $117.5 million, which will significantly bolster the company's financial resources for future initiatives.
- Underwriter Participation: The transaction was initiated by Lynx1 Capital Management, with participation from Deep Track Capital and Foresite Capital, while Stifel, Cantor Fitzgerald, and RBC Capital Markets serve as joint book-running managers, reflecting strong market confidence in the company.
- Closing Schedule: The offering is expected to close on April 30, indicating the company's active engagement in capital markets and urgent funding needs, which may influence the advancement of its upcoming projects.
- Market Reaction: Despite a 1% decline in GH Research's shares during premarket trading, the offering is still viewed as a positive step towards enhancing the company's financial position, potentially boosting investor confidence in the long run.
See More
